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1. The state of Bio-Ethics 
Biotechnology is defined as "the integration of natural and engineering 
sciences in order to achieve the application of organisms, cells, parts 
thereof and molecular analogues for products and services" and is the 
meeting point of different disciplines, originating in Biology, Chemistry, 
Biochemistry, Physics and Engineering. Historically, their interactions have 
resulted in a burst of industrial activities with a huge although ambiguous 
impact on the planet. Among the assets accrued are large 
distributions/accumulations of wealth, new food sources and new 
medicines. But there are also liabilities, such as environmental 
contamination and degradation of genomes. This is a wide, complex field. 
Accordingly, the professional activities and the personal responsibilities of 
biotechnologists are extremely diverse and the frequency by which 
scientists are confronted with decision-requiring situations increase 
exponentially with their proficiency. A proportion of the decisions to be 
made are momentous; they involve or may affect the well-being of other 
individuals, of society at large, of the environment, even the quality of life 
on Earth for the present and future generations. These decisions are of 
moral nature: while technical knowledge is indispensable to locate and 
evaluate the concrete alternatives, an appreciation of ethics and ethical 
issues is indispensable in making the choice between them. This choice 
may be on occasion difficult, considering the prevailing social, economic 
and political pressures. 
Another factor that adds stumbling blocks to the situation is the tendency of 
grouping all ethical issues concerned in any way with "life" under the label 
Bioethics which, in turn - by virtue of the perception of the general public 
and especially the media - is heavily skewed towards Medical Ethics and 
issues concerned with, e.g., human conception, prenatal testing, sex 
selection, health care, terminal care, psychotherapy. 
These are important and sensitive issues and the way they are approached 
is influenced by religious and socio-political decisions in society at large 
and also among the scientists. We feel that expansion and advances in 
other branches of ethics, e.g., Environmental, Biotechnological and 
Industrial Ethics are hampered by the overwhelming accent on Medical and 
personal problems and also by the fact that a certain polarization of 
opinions is artificially transferred out of context from the latter, thus blurring 
and freezing issues where consensus could be expected and would 
accelerate solutions. The unbalance among sub-disciplines is confirmed by 
a rapid survey of the 1998 Catalogue of Contracts in the field of Ethics, 
legal and social aspects of the Life Sciences issued by the European 
Commission. Out of 61 contracts, 33 (54%) are on Medical Bioethics, 22 
(36%) on biotechnological aspects and the rest on Communication and 
Public Perception. Even more significantly, the researchers involved in the 
first group are 415 (58%) while those engaged in the second group are only 
138 (19%). 
We are encouraged in the quest for better identification of BT-Ethics by the 
survey currently run jointly by the AAAS American Association for the 
Advancement of Science, a UNESCO World Commission on the Ethics of 
the Scientific Knowledge and Technology (COMEST); see 
www.nextwave.org) The survey seeks to identify the ethical issues that 
advances in science and technology are likely to raise in the 21st century. 
The results of the survey will provide first hand material to theoretical and 
educational work. 
Developments in Biotechnology have provided numerous issues and 
concerns of an ethical nature. These take the form of media and public 
alarm at the new products and process which involve the genetic 
modification of microbial, plant and animal materials. In particular we can 
point to the controversies which have arisen over: 
• the distribution of genetically engineered plant foodstuffs,  
• the use of a hormone to improve milk yields (Bovine Somatotrophin),  
• the cloning of sheep,  
• the ownership of human and other genes,  
• drugs which can be used to enhance human athletic performance 
(Erythropoietin and Growth Hormone),  
• vaccines,  
• xenotransplantation, 
• genetic enhancements.  
• In addition, we have to note that while some 700 Biotechnology 
companies have been recently instigated in Europe, the misbehaviour 
of the directors of several such companies has led to a decrease in 
public confidence in Biotechnology as a way of adding to human 
benefit. For example: 
• British Biotechnology was held to have overstated the benefits of an 
anticancer drug which was in clinical trials, 
• A company prevented the publication of trial data showing that an 
alternative material was of equivalent potency to their in-house 
product, 
• Endotronics inflated their sales of cell culture equipment artificially, 
• Genentech, without prior permission, took out a patent on Growth 
Hormone which was based on work which was done in the University 
of California. 
• A third type of ethical malpractice stems from the way in which 
laboratory research is effected. The literature is replete with examples 
of the way in which bench workers have: 
• falsified data,  
• fabricated data,  
• plagiarised the data and ideas of others,  
• obstructed and obfuscated the research of others so that they would 
be misled and held back, 
• had conflicts of interest, 
• been abused for whistle blowing, 
• prematurely released data to the press, 
• misused animals and humans in experimental situations and  
• have abused the supervisor-researcher relationship. 
• Biotechnology has the potential to provide major economic gains to 
society. It is a vital activity which can beneficially affect the health and 
longevity of humans and their animals. It is, therefore, imperative that 
we do all in our power to prevent this nascent industry from becoming 
moribund as a result of a growing malaise which could be generated 
by the ethical concerns delineated above. Not only must we provide a 
supportive environment for the development of the industry but we 
must also provide for the protection and fostering of the well-being of 
our citizens through the developments of the appropriate Science and 
Engineering. We hold that an essential means whereby these ends 
can be achieved is through the more thorough and informed posing 
and developing of ethical questions (for example, are we allowed to 
do research on cloning, stem cell research or transgenetic production 
of drugs? At which moment of the biotechnological process should 
there be attention to ethical problems?) and their translation into 
education and training of all putative Biotechnologists.  
• 2. Education 
• Among the consequences of biotechnological development, there is 
the creation of great wealth, with attendant effects on the global 
economy as well as on politics. Naturally, there is an intense 
competition for brains and markets among the most developed 
countries. We believe that the race is going to be decided on the 
grounds of education, and that the EU has a chance only if the next 
generation of leaders in this field will be scientifically advanced, 
socially aware and truly European. To take up this challenge, 
scientists and organizations concerned have founded the European 
Association for Higher Education in Biotechnology.  
• HEduBT was founded in Strasbourg in November 1995 and is the 
vehicle chosen to establish European titles in Biotechnology. The 
purpose of HEduBT is to develop European standards for both the 
PhD and MS in Biotechnology and to ensure that graduates from 
universities and research institutes all over the European Community 
obtain a qualification which is considered appropriate and is 
recognized by the biotechnology industry.  
• The qualification of HEduBT is provided by its membership, its organs 
and by the representation in its Scientific Board of European 
organizations such as: 
• CRE (Confederation of the European Union Rectors’ Conferences); 
• EMBO (European Molecular Biology Organization); 
• EFB (European Federation of Biotechnology). 
HEduBT identifies a combination of skills found in many different university 
systems, which together provide the multidisciplinary training which is 
needed in the rapidly developing area of Biotechnology. HEduBT’s raison 
d’être is that the complexity of the field must be met by a multi-dimensional 
education combining Science and international/interdisciplinary culture. 
Thus, to be awarded an EDBT - European Doctorate in Biotechnology - the 
required credits are earned by courses in technical disciplines and in 
interdisciplinary topics. Candidates must have spent a part of their research 
time in another European country, and produced a thesis of excellence. 
The requirements of training in interdisciplinary areas is exacting. A total of 
six credits should be earned by following courses and doing field work in 
Ethical, Social, Legal and Managerial aspects of Biotechnology (examples: 
Bioethics, Patenting, Environmental Sciences, Computer Science, etc.). 
The activity of HEduBT is well on its way, and, end 2000, the first ten 
European Doctorates titles have been awarded, while enrolled students 
(60) and the number of member Universities (30) and Institutes are 
increasing. However, in our experience, the most challenging tasks for the 
students has been to find ways to satisfy the EDBT requirements of 
international and interdisciplinary training, in particular the training in ethical 
issues pertaining to technology and its impact on Biological sciences. 
Today, in most universities, education in ethics is not part of the training of 
biotechnologists. This may be a consequence of the Socratic optimism 
trusting that good science is sufficient for good behaviour, but this "soft" 
approach is certainly a factor in the increasing number of mistakes, 
misdemeanours and worse, perpetrated at the interface of Biology and 
Industry and in the oblivion of posing questions about the social and 
fundamental acceptability of Biotechnology. In 1998, 1999 and 2000 
HEduBT has inspired the delivery of a number of courses in Bioethics and 
Public Perception, held in different European countries and attended by 
many EDBT students. 
 
 
  
